Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Jan;28(1):1-13.
doi: 10.1007/s10875-007-9126-7. Epub 2007 Sep 9.

Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3

Affiliations
Review

Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3

Alberto Mantovani et al. J Clin Immunol. 2008 Jan.

Abstract

Pentraxins are a family of multimeric pattern-recognition proteins highly conserved in evolution. Based on the primary structure of the subunit, the pentraxins are divided into two groups: short pentraxins and long pentraxins. C-reactive protein and serum amyloid P-component are classic short pentraxins produced in the liver, whereas the prototype of the long pentraxin family is PTX3. Innate immunity cells and vascular cells produce PTX3 in response to proinflammatory signals and Toll-like receptor engagement. PTX3 interacts with several ligands, including growth factors, extracellular matrix components, and selected pathogens, playing a role in complement activation, facilitating pathogen recognition, and acting as a predecessor of antibodies. In addition, PTX3 is essential in female fertility acting on the assembly of the cumulus oophorus extracellular matrix. Thus, PTX3 is a multifunctional soluble pattern recognition receptor acting as a nonredundant component of the humoral arm of innate immunity and involved in tuning inflammation, in matrix deposition and female fertility. Evidence suggests that PTX3 is a useful new serological marker, rapidly reflecting tissue inflammation and damage under diverse clinical conditions.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Immunol. 2003 Oct;33(10):2886-93 - PubMed
    1. J Leukoc Biol. 2004 Apr;75(4):649-56 - PubMed
    1. J Leukoc Biol. 2004 Jul;76(1):203-9 - PubMed
    1. Blood. 2006 Nov 15;108(10):3387-96 - PubMed
    1. Clin J Am Soc Nephrol. 2007 Sep;2(5):889-97 - PubMed

Publication types

MeSH terms

LinkOut - more resources